866-997-4948(US-Canada Toll Free)

Sicca Syndrome (Sjogren) - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : Jun 2017

Category :

Pharmaceutical

No. of Pages : 104 Pages

Sicca Syndrome (Sjogren) - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Sicca Syndrome (Sjogren) - Pipeline Review, H1 2017, provides an overview of the Sicca Syndrome (Sjogren) (Immunology) pipeline landscape.

Sjogrens syndrome is an autoimmune disease. It involves inflammation of glands and other tissues of the body. Symptoms include skin rashes or dry skin, vaginal dryness, persistent dry cough, prolonged fatigue, dry eye, dry mouth, joint pain, swelling and stiffness. Predisposing factors include age, sex and rheumatic disease.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Sicca Syndrome (Sjogren) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Sicca Syndrome (Sjogren) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Sicca Syndrome (Sjogren) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Sicca Syndrome (Sjogren) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 14, 4, 7 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Sicca Syndrome (Sjogren) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Sicca Syndrome (Sjogren) (Immunology).
- The pipeline guide reviews pipeline therapeutics for Sicca Syndrome (Sjogren) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Sicca Syndrome (Sjogren) (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Sicca Syndrome (Sjogren) (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Sicca Syndrome (Sjogren) (Immunology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Sicca Syndrome (Sjogren) (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Sicca Syndrome (Sjogren) (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Sicca Syndrome (Sjogren) - Overview
Sicca Syndrome (Sjogren) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Sicca Syndrome (Sjogren) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Sicca Syndrome (Sjogren) - Companies Involved in Therapeutics Development
Akari Therapeutics Plc
Amgen Inc
Atlantic Bio Sci LLC
Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
Galapagos NV
Gilead Sciences Inc
GlaxoSmithKline Plc
Immunwork Inc
MedImmune LLC
Novartis AG
Redx Pharma Plc
Samjin Pharmaceutical Co Ltd
UCB SA
XTL Biopharmaceuticals Ltd
Sicca Syndrome (Sjogren) - Drug Profiles
abatacept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ABS-11 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AMG-557 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
belimumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
belimumab + rituximab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-986142 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Type 1 Diabetes and Sjogrens Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CFZ-533 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Coversin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
edratide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
filgotinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GS-9876 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-2618960 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMSO-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
leniolisib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lulizumab pegol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3090106 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MEDI-4920 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MEDI-7734 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RDX-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RG-7625 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RSLV-132 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SA-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
seletalisib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TE-2324 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tirabrutinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VAY-736 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VM-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Sicca Syndrome (Sjogren) - Dormant Projects
Sicca Syndrome (Sjogren) - Discontinued Products
Sicca Syndrome (Sjogren) - Product Development Milestones
Featured News & Press Releases
Apr 05, 2017: XTL Biopharmaceuticals Unveils Expanded hCDR1 Preclinical Data for the Treatment of Sjogrens Syndrome
Apr 04, 2017: Galapagos announces three new Phase 2 Proof-of-Concept studiesbwith filgotinib
Feb 13, 2017: XTL Biopharmaceuticals Expands Clinical Advisory Board to Support Phase II Study of HCDR1 in Sjogrens Syndrome
Jan 05, 2017: XTL Biopharmaceuticals' Preclinical Studies of hCDR1 Demonstrate Therapeutic Potental In the Treatment of Sjogrens Syndrome
Apr 22, 2011: Breakthrough study links Type 1 diabetes and Sjogrens syndrome
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Sicca Syndrome (Sjogren), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Sicca Syndrome (Sjogren) - Pipeline by Akari Therapeutics Plc, H1 2017
Sicca Syndrome (Sjogren) - Pipeline by Amgen Inc, H1 2017
Sicca Syndrome (Sjogren) - Pipeline by Atlantic Bio Sci LLC, H1 2017
Sicca Syndrome (Sjogren) - Pipeline by Bristol-Myers Squibb Company, H1 2017
Sicca Syndrome (Sjogren) - Pipeline by Eli Lilly and Company, H1 2017
Sicca Syndrome (Sjogren) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Sicca Syndrome (Sjogren) - Pipeline by Galapagos NV, H1 2017
Sicca Syndrome (Sjogren) - Pipeline by Gilead Sciences Inc, H1 2017
Sicca Syndrome (Sjogren) - Pipeline by GlaxoSmithKline Plc, H1 2017
Sicca Syndrome (Sjogren) - Pipeline by Immunwork Inc, H1 2017
Sicca Syndrome (Sjogren) - Pipeline by MedImmune LLC, H1 2017
Sicca Syndrome (Sjogren) - Pipeline by Novartis AG, H1 2017
Sicca Syndrome (Sjogren) - Pipeline by Redx Pharma Plc, H1 2017
Sicca Syndrome (Sjogren) - Pipeline by Samjin Pharmaceutical Co Ltd, H1 2017
Sicca Syndrome (Sjogren) - Pipeline by UCB SA, H1 2017
Sicca Syndrome (Sjogren) - Pipeline by XTL Biopharmaceuticals Ltd, H1 2017
Sicca Syndrome (Sjogren) - Dormant Projects, H1 2017
Sicca Syndrome (Sjogren) - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Sicca Syndrome (Sjogren), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *